Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

A moderate metal-binding hydrazone meets the criteria for a bioinorganic approach towards Parkinson's disease: Therapeutic potential, blood-brain barrier crossing evaluation and preliminary toxicological studies

Lookup NU author(s): Professor Tiago OuteiroORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2017 Elsevier Inc. Alzheimer's and Parkinson's diseases share similar amyloidogenic mechanisms, in which metal ions might play an important role. In this last neuropathy, misfolding and aggregation of α-synuclein (α-Syn) are crucial pathological events. A moderate metal-binding compound, namely, 8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone (INHHQ), which was previously reported as a potential ‘Metal-Protein Attenuating Compound’ for Alzheimer's treatment, is well-tolerated by healthy Wistar rats and does not alter their major organ weights, as well as the tissues' reduced glutathione and biometal levels, at a concentration of 200 mg kg− 1. INHHQ definitively crosses the blood-brain barrier and can be detected in the brain of rats so late as 24 h after intraperitoneal administration. After 48 h, brain clearance is complete. INHHQ is able to disrupt, in vitro, anomalous copper-α-Syn interactions, through a mechanism probably involving metal ions sequestering. This compound is non-toxic to H4 (human neuroglioma) cells and partially inhibits intracellular α-Syn oligomerization. INHHQ, thus, shows definite potential as a therapeutic agent against Parkinson's as well.


Publication metadata

Author(s): Cukierman DS, Pinheiro AB, Castiñeiras-Filho SLP, da Silva ASP, Miotto MC, De Falco A, de P Ribeiro T, Maisonette S, da Cunha ALMC, Hauser-Davis RA, Landeira-Fernandez J, Aucélio RQ, Outeiro TF, Pereira MD, Fernández CO, Rey NA

Publication type: Article

Publication status: Published

Journal: Journal of Inorganic Biochemistry

Year: 2017

Volume: 170

Pages: 160-168

Print publication date: 01/05/2017

Online publication date: 22/02/2017

Acceptance date: 20/02/2017

ISSN (print): 0162-0134

ISSN (electronic): 1873-3344

Publisher: Elsevier Inc.

URL: https://doi.org/10.1016/j.jinorgbio.2017.02.020

DOI: 10.1016/j.jinorgbio.2017.02.020

PubMed id: 28249224


Altmetrics

Altmetrics provided by Altmetric


Share